Liquid NAD+ Anti-Aging Drink | NR Berry Stick Packs for NAD+ & Sirtuin Support

NAD+ precursors in drinkable form — built for people who don't want to swallow more capsules, who already have a morning routine where adding a drink is easier than adding another pill bottle, and who travel and don't want a carry-on stuffed with HDPE bottles. Single-serve berry stick packet, dissolves in 30 seconds in 7–10 oz of cold water, no scoops, no measuring, TSA-friendly, no artificial colors, no added sugar bombs. Same NAD+-pathway biology as our NR Hard Capsules and Pure NMN 500mg — just delivered through the format you'll actually take every single day.

The 30-second answer

• Drink format, soluble delivery — absorption begins in the oral mucosa and continues through the upper GI without waiting on capsule disintegration. Powder dissolved in 7–10 oz cold water reaches plasma faster than the equivalent dose of compressed capsules.
• Nicotinamide Riboside (NR) at the center — the NAD+ precursor with the longest human clinical-trial track record. Trial-validated daily dosing (Trammell 2016 Nat Commun, Conze 2019 Sci Rep, Martens 2018 Nat Commun, Brakedal 2022 Cell Metab NADPARK).
• Clean berry flavor, no sweet bombs — no artificial colors, no sucralose, no stevia avalanche; mixes cleanly so it doesn't taste medicinal.
• Single-serve packets — TSA-friendly, no scoops, no measuring spoons, no spilling powder in your kitchen drawer. Stable at room temperature, single-use foil-laminated packaging.
• Foundation-tier daily NAD+ support — pairs cleanly with Resveratrol 600mg, Pterostilbene 100mg, TMG 1000mg, Apigenin 50mg, and the rest of the longevity stack — never redundant with capsules; many users alternate or stack the formats.
• Best for: people who don't tolerate capsules well, those building a morning-drink ritual, anyone who finds drink supplements easier to remember than pill bottles, frequent travelers, and users who want NAD+ pathway support that's literally pleasant to take.

Why NAD+ matters — the foundational coenzyme behind cellular aging

NAD+ (nicotinamide adenine dinucleotide) is one of the most foundational coenzymes in human biology. Every nucleated cell in your body uses it. It runs the electron transport chain in your mitochondria — the system that converts food and oxygen into ATP, the molecular currency of energy. It is the obligate substrate of the sirtuin family of NAD+-dependent deacetylases (SIRT1–SIRT7), which silence pro-aging gene programs, regulate inflammation, drive DNA-damage response, and govern mitochondrial biogenesis. It powers the PARP enzymes that detect and repair single- and double-strand DNA breaks every day. It is consumed by CD38, the cell-surface ectoenzyme whose age-related upregulation is one of the largest mechanistic explanations for falling NAD+ pools (Camacho-Pereira 2016 Cell Metabolism). Without enough NAD+, none of these systems run properly.

The problem: NAD+ levels drop sharply with age. Massudi 2012 (PLOS ONE) showed roughly a ~50% decline in skin NAD+ between the 20s and 50s with the decline accelerating after that. Yoshino 2011 (Cell Metabolism) replicated this multi-tissue in mouse models — liver, muscle, pancreas, white adipose tissue, brown adipose tissue, brain — with parallel declines in NAMPT (the rate-limiting salvage-pathway enzyme). Camacho-Pereira 2016 mapped the decline mechanistically to age-related CD38 upregulation acting as an NAD+ "sink" rather than to NAMPT alone. By the time most people notice "feeling older" — slower recovery, less morning energy, fuzzier focus, less stress resilience — NAD+ depletion is already one of the underlying biochemical drivers, sitting upstream of the López-Otín 2013 Cell hallmarks of aging (mitochondrial dysfunction, deregulated nutrient sensing, genomic instability, cellular senescence) and folded explicitly into the López-Otín 2023 Cell integrated-hallmarks update.

You can't supplement NAD+ directly very efficiently in most oral formats — the molecule is too large and polar to cross plasma membranes intact at meaningful doses. That's why the field moved to precursors: smaller molecules (NR, NMN, niacinamide, niacin) that your cells convert into NAD+ on the inside via well-mapped enzymatic routes. NR is the precursor with the most published human-clinical-trial evidence at this point — covering whole-blood NAD+ rise, cardiovascular endpoints, brain NAD+, muscle NAD+, insulin sensitivity, and exercise physiology. It is the active core of this drink.

For a deeper introduction read What is NAD+? A beginner's guide and NMN vs NR — which NAD+ precursor actually works better.

Why drink format — not just preference, real biology

Capsules and drink mixes are not biologically equivalent on day one of dosing. Three things change when you take an NAD+ precursor as a dissolved drink instead of a hard capsule:

1. Onset. A hard-shell HPMC capsule needs 5–15 minutes to disintegrate in the stomach before the contents become available for absorption (USP <701> disintegration spec is ≤30 minutes for HPMC capsules; in practice typically 5–12 minutes). A dissolved drink presents the precursor to the intestinal mucosa within 30 seconds. This narrows the gap between "taking the supplement" and "the molecule arriving at the absorption surface" to roughly the gastric-emptying half-time of liquid (10–20 minutes for water on an empty stomach).
2. Buccal and upper-GI absorption. NR has been shown to absorb partially via the oral mucosa and proximal small intestine via the equilibrative nucleoside transporters ENT1 and ENT2 (Ratajczak 2016 Nat Commun). A dissolved drink is in contact with absorptive surfaces immediately; a capsule is not.
3. Adherence — the variable that dwarfs everything else. The single largest determinant of long-term outcomes from any daily supplement is whether you actually take it every day for months. Trial endpoints in NAD+ research (Conze 2019, Brakedal 2022 NADPARK 1g/day for 30 weeks, Pirinen 2020 1g/day for 4 months) require weeks-to-months of compliance. Capsule fatigue, capsule aversion, "I forgot, I'll do it tomorrow" — these account for far more lost benefit than any pharmacokinetic difference between formats. A drink that's actually pleasant to take every morning beats a capsule that ends up rationed.

This product isn't trying to replace capsule NAD+ precursors — it's the format that wins for a specific user. If you already happily take capsules, our NR Hard Capsules and Pure NMN 500mg remain the highest-density precursor delivery per dollar. If you have capsule fatigue, swallowing aversion, traveler-luggage limits, or a strong morning-drink ritual where adding one stick packet is invisible, this format quietly wins on adherence — the variable that matters most.

Why Nicotinamide Riboside (NR) specifically

The four NAD+ precursors a cell can use are NR (Nicotinamide Riboside), NMN (Nicotinamide Mononucleotide), NAM (Niacinamide / Nicotinamide), and NA (Niacin / Nicotinic Acid). Each has trade-offs:

• NR — phosphorylated to NMN by NRK1/NRK2 (Bieganowski & Brenner 2004 Cell), then adenylylated to NAD+ by NMNAT1/2/3. Crosses cell membranes intact via ENT1/2 (Ratajczak 2016). Most extensively human-trialed precursor (Trammell 2016, Conze 2019, Martens 2018, Dollerup 2018, Elhassan 2019, Brakedal 2022, Pirinen 2020, Dellinger 2017). No flushing.
• NMN — one step closer to NAD+ but reportedly enters cells via the proposed Slc12a8 transporter (Grozio 2019 Nature Metabolism) or via extracellular conversion to NR by CD73 then re-uptake. Strong human-trial bench at the 250–1000mg dose range (Yoshino 2021 Science, Yi 2022, Liao 2021, Igarashi 2022). Functionally interchangeable with NR for most users; many longevity practitioners stack both to hedge across the parallel salvage entry points.
• NAM — cheap, abundant, but at high doses inhibits sirtuins (Bitterman 2002 JBC) by acting as a product-inhibitor. Useful as a B3-vitamin source; less ideal as a sirtuin-substrate booster.
• NA — raises NAD+ but causes prostaglandin-mediated flushing at meaningful doses unless given as ER-niacin under medical supervision.

NR is the precursor with the densest human evidence base at this dose range, the cleanest tolerability profile, and parallel absorption pathways (ENT1/2 plus CD73→NR conversion) that make it format-flexible for liquid delivery. That's why it sits at the center of this drink.

Mechanism — how NR becomes NAD+ inside your cells

NR taken orally has the following well-mapped fate (Ratajczak 2016, Trammell 2016, Cantó 2015 Cell Metabolism):

1. Absorption. NR is absorbed in the oral mucosa, stomach, and proximal small intestine via the equilibrative nucleoside transporters ENT1 and ENT2 (encoded by SLC29A1 / SLC29A2). It does not require the proposed Slc12a8 transporter that NMN appears to use. Plasma NR rises within 30–120 minutes; whole-blood NAD+ rises within 8 hours and remains elevated for 24+ hours after a single dose (Trammell 2016, Conze 2019).

2. NRK1/NRK2 phosphorylation. Inside the cell, NR is phosphorylated to NMN by the NR kinases NRK1 (ubiquitous) and NRK2 (tissue-restricted to muscle, heart, brain). This step was discovered and characterized in Bieganowski & Brenner 2004 Cell. NRK1 expression is the primary rate-limiting determinant of how quickly a given tissue converts NR to NAD+.

3. NMNAT1/2/3 adenylylation. NMN is then adenylylated to NAD+ by the three nicotinamide mononucleotide adenylyltransferase isoforms — NMNAT1 (nucleus), NMNAT2 (Golgi/cytosol), NMNAT3 (mitochondria). This step compartmentalizes NAD+ synthesis to where it's needed.

4. Mitochondrial uptake. Mitochondrial NAD+ uptake is governed by the SLC25A51 transporter, identified in 2020 by Luongo et al. (Nature). This was the answer to one of the longest-standing questions in NAD+ biology — how the cytosolic and mitochondrial NAD+ pools communicate.

5. Consumption. NAD+ is consumed by three classes of enzymes: sirtuins (SIRT1–SIRT7) deacetylate substrate proteins using NAD+ as cofactor; PARPs (PARP1, PARP2, etc.) consume NAD+ during DNA-damage repair; and CD38 hydrolyzes NAD+ at a stoichiometry of roughly 100 NAD+ molecules per cyclic-ADP-ribose product. CD38 is the dominant age-related sink (Camacho-Pereira 2016) — which is why Apigenin (a flavonoid CD38 inhibitor; Escande 2013 Diabetes) is a logical stack partner.

6. Salvage and methylation. NAM — the byproduct of every sirtuin/PARP/CD38 NAD+-consuming reaction — is recycled back to NMN by NAMPT, the rate-limiting salvage-pathway enzyme. Excess NAM is methylated to 1-MNA (1-methylnicotinamide) by NNMT, drawing from the SAM (S-adenosylmethionine) methylation pool. This is why methyl-donor support — TMG (trimethylglycine) — pairs with daily NR/NMN dosing, especially at higher doses (1g+/day) and for users with MTHFR variants or marginal B12 status. 1-MNA appearance in urine is the standard pharmacodynamic biomarker confirming NAD+ flux is occurring (Trammell 2016).

Clinical evidence base for NR

NR has the densest human-trial bench of any NAD+ precursor. Selected trials at doses spanning 100mg – 3000mg/day:

Read together: NR is one of the few longevity-positioned compounds where the human evidence base actually maps cleanly onto the mechanistic story. NAD+ rises (Trammell, Conze, Brakedal, Elhassan), tissue penetration is documented (muscle in Elhassan/Remie/Stocks; CSF/brain in Brakedal NADPARK), cardiovascular signal exists (Martens 2018), safety is established up to 3g/day (Brakedal 2023 NR-SAFE), and the mechanism (NRK1→NMN→NAD+) is structurally proven. That's why NR is the active core of this drink — not because it's the only NAD+ precursor that works, but because it has the most complete human evidence base at this dose range.

Drink-format NAD+ — comparing what's actually on the market

Once you commit to drink format, the next question is what kind. Six paths exist:

Where this drink sits in our NAD+ family

True Health Protocol's NAD+ line was built so each product owns a distinct spot in the precursor / activator / cofactor / convenience space — not as duplicates. The seven distinct entry points:

For most users, the right answer is one drink-format product for the morning ritual + one sirtuin activator (Resveratrol or Pterostilbene) + methyl-donor support (TMG) + the rest of the foundational stack (Magnesium, Vit-D, Omega-3). Browse the full NAD+ Family at /collections/nad-family.

Bioavailability deep-dive — what we know about drink-format NR PK

The published NR pharmacokinetic profile (Trammell 2016, Airhart 2017, Conze 2019) was established in capsule and powder formats. Key findings translate to drink delivery:

• Plasma NR peaks 30–120 minutes after oral dosing.
• Whole-blood NAD+ rises within 8 hours and remains elevated 24+ hours after a single dose.
• Dose-linearity documented in Conze 2019 across 100/300/1000mg/day × 8wk: ~22% / 51% / 142% NAD+ rise respectively. The dose-response is approximately log-linear in this range.
• 1-MNA urinary appearance rises within 24 hours, confirming the NAD+→NAM→1-MNA flux is occurring (Trammell 2016).
• Steady-state NAD+ elevation is reached by approximately week 1–2 of daily dosing; further dosing maintains rather than progressively elevates.
• Tissue distribution documented in muscle (Elhassan, Remie, Stocks), CSF/brain (Brakedal NADPARK), and liver (preclinical). Mitochondrial NAD+ rise is governed by SLC25A51 capacity (Luongo 2020 Nature).

Drink-format delivery vs capsule delivery should not change steady-state NAD+ levels over weeks — both end up at the same plateau if dosed daily — but it does compress the time-to-onset of each individual dose, and (more importantly for outcomes) it materially raises the probability that you actually take it every day.

Stacking — what to pair with daily NAD+ drink

NR alone raises NAD+ but doesn't address the consumer side (CD38), the sirtuin-activator side (resveratrol/pterostilbene), or the methylation tax (TMG). The mechanistically-coherent stack:

Sirtuin substrate + activator pair

NR/NMN provides the substrate. Sirtuin-activating compounds — Resveratrol 600mg (Howitz 2003 Nature; Park 2012 Cell; Lagouge 2006 Cell) and Pterostilbene 100mg (Riche 2014 trial) — allosterically activate SIRT1. Pair the NAD+ precursor drink with one of these. This is the “Sinclair-style” canonical longevity pairing.

Methylation support

NAM — the byproduct of every sirtuin reaction — is methylated to 1-MNA by NNMT, drawing on the SAM pool. TMG 1000mg donates a methyl group to homocysteine, regenerating methionine and protecting the SAM pool (Olthof 2003 Am J Clin Nutr; McRae 2013 Cardiol Res Pract). Paired with NR/NMN especially at higher doses or in users with MTHFR variants. Glycine 1500mg is a parallel methyl-buffer.

CD38 reduction

CD38 is the dominant age-related NAD+ sink (Camacho-Pereira 2016). Flavonoid CD38 inhibitors — Apigenin 50mg (Escande 2013 Diabetes), Quercetin 500mg, Fisetin 500mg — reduce the consumer side of the equation. Stacking CD38 reduction with NAD+ precursor supply addresses both sides of the NAD+ balance.

Mitochondrial layer

NAD+ runs the electron-transport chain. CoQ10 400mg shuttles electrons from Complex I/II to Complex III. PQQ 20mg drives mitochondrial biogenesis via PGC-1α. Urolithin A 500mg activates PINK1/Parkin-driven mitophagy — clearing dysfunctional mitochondria so the new biogenesis isn't replacing them with damaged copies. Ca-AKG 1000mg feeds the TCA cycle. Together this is the mitochondrial-renewal layer.

Autophagy and proteostasis

Spermidine 10mg initiates autophagy via eIF5A hypusination (Zhang 2019 Mol Cell) and EP300 inhibition (Pietrocola 2015 Cell Cycle). Reciprocal with NAD+ precursors — SIRT1 deacetylates autophagy proteins ATG5/ATG7/LC3 (Lee 2008 PNAS); spermidine independently triggers the autophagy machinery. Not redundant.

AMPK pathway

Berberine 500mg activates AMPK (Yin 2008 Metabolism). AMPK upregulates NAMPT (the rate-limiting NAD+ salvage enzyme) and phosphorylates SIRT1 substrates. Reciprocal feedback: SIRT1 deacetylates and activates LKB1 which phosphorylates and activates AMPK. The two pathways amplify each other.

Antioxidant + glutathione

NAC 600mg + Glutathione 500mg + Glycine 1500mg form the GlyNAC stack (Sekhar 2021 Clin Transl Med) — restores glutathione synthesis in older adults whose mitochondrial GSH is depleted. Alpha-Lipoic Acid 600mg recycles vitamin C and glutathione. Liposomal Vitamin C 1000mg is the membrane-protected ascorbate. Astaxanthin 12mg is the membrane-resident lipid-soluble antioxidant.

Foundational layer

Magnesium Glycinate 400mg, Vitamin D3 5000 IU + K2, Omega-3 2000mg, Curcumin 1000mg, Ashwagandha KSM-66 600mg, Creatine 1000mg, Taurine 1000mg. These don't extend the longevity story per se — they make sure your foundation isn't sabotaging the longevity layer.

Skin / collagen pairing

If skin appearance is an outcome you care about: Marine Collagen 5000mg + Hyaluronic Acid 200mg + Vit C + Biotin 10,000 mcg form the substrate / hydration / cofactor stack the Beauty & Longevity Stack bundle was built around. NAD+ supports skin via SIRT1-mediated extracellular-matrix maintenance; the collagen layer is downstream of that.

For a built version of this stack as a single bundle, see the Longevity Stack Bundle (NMN 500mg + Resveratrol 600mg) or the Longevity Essentials collection.

Week-by-week — what to expect

NAD+ pathway support is built on consistency. Onset is not subjective on day one; the changes you eventually notice come from sustained tissue-level NAD+ elevation over weeks-to-months. Anchored to the published trial timepoints:

• Day 1 – week 1. Whole-blood NAD+ rises within 8 hours of the first dose (Trammell 2016) and steady-states by approximately day 7–14 (Conze 2019, Airhart 2017). Most users do not feel anything subjective in this window. If you feel a sharp stimulant-like kick, it's not NAD+ — it's a placebo or excipient response.
• Weeks 2–4. Some users report subtle morning-energy / less afternoon-crash signal as mitochondrial NAD+ elevates and the SLC25A51-governed compartment fills. This is highly variable. Trial endpoints at this timepoint tend to be biomarker-level (Elhassan 2019 IL-6/IL-5/IL-2 reduction at 21 days; Conze 2019 NAD+ elevation at 8 weeks).
• Weeks 4–8. Functional outcomes start to appear in the trial bench: Martens 2018 cardiovascular signal at 6 weeks (~10mmHg SBP drop in elevated-BP subgroup, aortic-stiffness reduction); Igarashi 2022 functional outcomes (SARC-F, 5x sit-to-stand) at 12 weeks. Subjectively users often report better recovery from exercise, better sleep depth, more stable energy.
• Weeks 8–12. Trial-published endpoints in this window include cardiovascular (Martens), glucose handling (Yoshino 2021 NMN parallel; Dollerup 2018 NR), sleep, cognitive subjective (Kim 2022 NMN parallel). This is when most users say they "wouldn't go without it" without being able to point to a single dramatic change.
• 3–6 months. Sustained pathway support; this is where the López-Otín hallmarks-of-aging integration is theorized to compound. The published trial bench thins out past 6 months — longest published trials are Brakedal NADPARK (30wk) and Pirinen 2020 (4 months). Subjective improvements at this stage are typically described as "normalcy I didn't know I'd lost".
• 6+ months. Long-term safety established up to 3g/day (Brakedal 2023 NR-SAFE) and 2g/day for 14 days (Pencina 2023 NMN parallel). No published evidence base out past 4 months for NR specifically; long-term users typically continue based on biomarker stability and functional outcomes.
• Stop dosing. Whole-blood NAD+ returns toward baseline within ~30 days of cessation (Conze 2019). This is one of the cleaner reasons NAD+ pathway support is positioned as a daily foundation rather than a cycle.

What this product is — and is NOT

• Is: a daily-foundation NAD+ precursor delivered in a format you'll actually take. The drink-mix path to NR's well-established human-trial benefit.
• Is NOT: a stimulant. Don't expect a coffee-like kick.
• Is NOT: a treatment for any disease. It is a dietary supplement; statements have not been evaluated by FDA.
• Is NOT: a one-month experiment that will visibly transform you. The trial bench requires weeks-to-months for endpoint readouts.
• Is NOT: a sleep aid. SIRT1 has indirect circadian-rhythm interactions (Asher 2008 Cell SIRT1-BMAL1/CLOCK) but NR is not a sedative; if sleep is the primary goal, see Magnesium Glycinate or Glycine.
• Is NOT: a substitute for the foundational layer. If your magnesium, omega-3, vitamin D, sleep, or training are broken, NR won't compensate.
• Is NOT: redundant with our NR Hard Capsules — it's a delivery-format alternative for users who prefer drinks. Many users alternate or stack the two.
• Is NOT: a sirtuin activator on its own. NR provides substrate; sirtuin activation comes from Resveratrol/Pterostilbene/CR-mimetic compounds. The full benefit is the pair.

Common mistakes to avoid

1. Quitting at week 4. Most published functional endpoints land in weeks 6–12. Quitting early loses the benefit.
2. Expecting a stimulant kick. NAD+ is a cofactor, not a stimulant. The change is subtle, sustained, and biomarker-level — not a rush.
3. Skipping methylation support at higher doses. If you're at ≥500mg/day NR plus an additional NMN dose, the methylation pool draws down. Add TMG.
4. NR without sirtuin activator. Substrate without activator captures only part of the benefit. Pair with Resveratrol or Pterostilbene.
5. Stacking NAD+ on a broken foundation. If sleep is <6h, magnesium status is poor, training is absent, and stress-cortisol is unmanaged, NAD+ pathway support is not the highest-leverage thing you can fix.
6. Dosing late in the day. Igarashi 2022 (NMN parallel) found AM dosing > PM dosing on functional endpoints. Mechanistic rationale: SIRT1 has circadian co-regulation with BMAL1/CLOCK; activating SIRT1 substrate when the circadian machinery expects it (morning) is the trial-validated path.
7. Storing in humid environments. Single-serve foil packets are stable, but bulk-cut open packets exposed to humidity will gradually degrade. Use within the dose interval, store unused packets cool and dark.

Daily protocol

1. Timing: Morning, ideally before breakfast or with first water of the day. Aligns with circadian SIRT1 activity.
2. Dose: 1 stick packet daily. Mix in 7–10 oz cold water (or as preferred — some users add to morning electrolyte drink, post-workout shake, or smoothie).
3. With food vs. fasted: Either works. NR absorption is not strongly food-dependent. If you experience mild GI upset on an empty stomach, take with food.
4. Pair with: A sirtuin activator (Resveratrol 600mg or Pterostilbene 100mg) taken with a fat-containing meal for best absorption. TMG 1000mg for methylation support if dosing ≥500mg total daily NR.
5. Consistency vs. timing: Daily dosing matters far more than which hour you take it. Pick a time you'll keep.
6. Missed dose: Skip and resume next day. Don't double-dose to "catch up." Steady-state NAD+ is robust to single missed doses.
7. Travel: Single-serve foil packets are TSA-friendly in carry-on. No bottle, no scoop, no measuring. One of the format's strongest practical advantages.
8. Cycling: Not required. NR has been studied at daily dosing for up to 30 weeks (Brakedal 2022 NADPARK) without tolerance development or required wash-out. Some practitioners cycle every 6–12 months as a personal-preference precaution; published evidence does not require it.
9. Duration: Months-to-years. NAD+ pathway support is a foundation, not a cycle.

Who this is for

• Adults 35+ wanting daily NAD+ pathway support without committing to another capsule bottle.
• Anyone with capsule fatigue or swallowing aversion.
• Travelers who want NAD+ support that fits in a luggage pocket.
• Users who already have a morning-drink ritual (electrolytes, greens, coffee) where adding a stick packet is invisible.
• Capsule users who occasionally want to alternate format.
• Pre-workout users who want NAD+ support before training (mitochondrial / energy positioning).
• Vegan and gluten-free users (no animal-derived ingredients, no gluten in formulation).
• Users building or maintaining a longevity stack who want one of the seven NAD+ entry points to be drink-format.

Who this is NOT for

• Pregnant or breastfeeding women (insufficient safety data for pregnancy).
• Children under 18 (no pediatric trial data).
• Users on chemotherapy or active cancer treatment without oncology consultation (NAD+ supports cell proliferation pathways; coordinate with oncology).
• Users seeking acute high-dose NAD+ delivery (IV therapy is a different category).
• Users with severe MTHFR variants who can't tolerate methyl loads — pair carefully with TMG and discuss with your physician.
• Users seeking same-day stimulant-like effects.

Safety, contraindications, interactions

• Pregnancy / breastfeeding: Not recommended. No published safety data for NR in pregnancy.
• Cancer / chemotherapy: Coordinate with oncology. NAD+ supports proliferative pathways; the literature on NAD+ precursor + cancer is mixed and context-dependent (Yaku 2018 Front Oncol review).
• Anticoagulants: No direct NR-anticoagulant interaction documented, but if stacked with Resveratrol (mild antiplatelet effect) advise caution and physician input. Stop 7–14 days pre-surgery as a general supplement-stack precaution.
• Antihypertensives: Martens 2018 showed ~10mmHg systolic-BP drop in elevated-BP subgroup. If on antihypertensive medication, monitor and discuss with your physician.
• Diabetes medications: NR has shown insulin-sensitization signal in some trials. Monitor blood glucose if on insulin or sulfonylureas; coordinate with your physician.
• Psychiatric / sleep medications: No direct interaction documented. Indirect SIRT1-circadian effects are subtle.
• MTHFR / methylation: Higher doses (>500mg/day) draw on the SAM pool via NNMT. Pair with TMG; consider B-vitamin status review.
• Mild GI: <5% of users in published trials report mild GI upset, headache, or transient flushing. Typically resolves with food or dose split.
• Upper-dose ceiling: Brakedal 2023 NR-SAFE established tolerability of 3000mg/day for 4 weeks with no serious AEs. Standard daily-foundation dosing is in the 250–1000mg range.
• Drug-test status: NR is not a banned substance under WADA or NCAA codes. Always cross-check current versions of the relevant codes if you compete.

Quality, sourcing, and manufacturing

True Health Protocol's Liquid NAD+ stick packs are manufactured in a 21 CFR Part 111 cGMP-compliant US facility. Per-batch QC includes:

• Identity testing: NR HPLC identity and purity (≥98% spec) confirmed by mass-spec orthogonal verification.
• Heavy metals: USP <232> panel (lead, cadmium, mercury, arsenic) at California Proposition 65 thresholds.
• Residual solvents: USP <467> panel.
• Microbial: USP <2021> total aerobic count, total yeast/mold, plus pathogen panel for E. coli, Salmonella, Staph aureus.
• Pesticide residues: USP <561>.
• Endotoxin: Specification confirmed per batch.
• Stability: ≥24-month room-temperature shelf life in foil-laminated single-serve sachets. Foil-laminate construction protects against UV, oxygen ingress, and humidity.
• Allergens: No gluten, no dairy, no soy, no nuts. Manufactured in a facility that handles common allergens; per-batch allergen panel applied.
• Sweeteners: Naturally flavored berry; no artificial colors, no high-fructose corn syrup, no sucralose flood.
• Single-source contract manufacturer audit: Same audited facility across batches, not lowest-bidder rotation.
• No proprietary blends: Per-stick NR mass disclosed on the supplement-facts panel.

FAQ

How much NR is in each stick packet? Per supplement-facts panel on the packaging. Designed to deliver a daily-foundation NR dose in a single stick.

Is this NR or NMN? NR (Nicotinamide Riboside). For the NMN drink mix, see NAD+ 1000mg Pure Focus Formula which combines NR with Resveratrol, PQQ, and Quercetin.

Can I take this with NMN? Yes. Many users stack both precursors to hedge across the parallel salvage entry points (NRK1/NRK2 for NR; Slc12a8 + CD73→NR conversion for NMN). Pair with TMG for methylation support.

Will I feel something on day one? Probably not anything dramatic. NAD+ is a cofactor, not a stimulant. The published trial bench requires weeks-to-months for measurable functional endpoints. If you feel a sharp kick, it's likely placebo or an excipient response.

How long until I notice anything? Highly variable. Some users report subtle morning-energy / sleep / recovery changes by week 2–4. Trial-published functional outcomes typically land in weeks 6–12 (Martens 2018 cardiovascular at 6wk; Igarashi 2022 functional at 12wk).

Can I take this at night? You can, but Igarashi 2022 (NMN parallel) found AM > PM dosing on functional endpoints. The mechanism is circadian: SIRT1 has documented co-regulation with BMAL1/CLOCK (Asher 2008 Cell). Morning is the trial-validated time.

Should I cycle? Not required by the published evidence. Brakedal 2022 NADPARK ran 1g/day for 30 weeks without tolerance or wash-out. Some practitioners cycle every 6–12 months as a personal precaution; published evidence does not require it.

Drink format vs capsule — which is better? Pharmacokinetically very similar at steady-state (both reach the same NAD+ plateau over weeks). Drink format compresses single-dose onset slightly and materially improves adherence for capsule-averse users. Pick the format you'll actually take every day — that beats every PK difference.

Can I take this with my coffee or breakfast? Yes. NR absorption is not strongly food-dependent. Adding the stick packet to your existing morning ritual is the single best way to ensure adherence.

What does it taste like? Clean berry. No artificial colors, no sucralose flood, no metallic NR aftertaste.

Is there caffeine in this? No. This is a pure NAD+ precursor formulation, not an energy drink.

Sugar content? Minimal. No added sugar bombs. Check the supplement-facts panel for exact carb/sugar grams.

Does this break a fast? Functionally yes (anything that hits the GI tract breaks autophagy-strict fasting protocols). Caloric content is minimal, so for time-restricted-eating windows it's negligible. For strict autophagy fasts, take during your eating window.

Is this vegan? Yes. No animal-derived ingredients in the powder formulation.

Gluten free? Yes.

Drug-test status? NR is not a WADA or NCAA banned substance. Always cross-check current versions of the relevant codes if you compete.

Can I open multiple packets and dose-split throughout the day? Yes, though daily morning dosing is the trial-validated standard. Multi-dose-per-day is sometimes used in clinical trials at ≥1g/day total dose to smooth GI tolerability.

Can I take during pregnancy? Not recommended. No published safety data for NR in pregnancy or lactation.

Can I take during cancer treatment? Coordinate with your oncology team. NAD+ supports proliferative pathways; the literature on NAD+ precursors in cancer is mixed and context-dependent.

Why is this format more expensive per dose than capsules? Single-serve foil-laminated stick packets cost more than HDPE bulk-bottle capsules to produce. The cost is the format, not the active ingredient. If price-per-NR-mg is your primary criterion, the capsule format wins.

Can I take this with an SSRI / antidepressant / blood pressure medication? No direct interactions documented. Discuss with your prescribing physician, particularly for antihypertensives (Martens 2018 SBP signal).

Will this help with sleep? Indirectly, possibly. SIRT1-BMAL1/CLOCK circadian interactions (Asher 2008 Cell) suggest secondary sleep-architecture effects in some users. Direct sleep effects are not the primary positioning — for sleep-first protocols see Magnesium Glycinate or Glycine 1500mg.

Will this help with hair growth? Indirectly. NAD+ supports the SIRT1-mediated extracellular-matrix maintenance that underlies skin and hair follicle health. For direct hair-cycle support see Biotin 10,000 mcg, Marine Collagen 5000mg, and Spermidine 10mg (Rinaldi 2018 anagen-cycle data).

What if I miss a day? No problem. Resume next day. NAD+ pathway support is built on sustained consistency over weeks, not single-dose rescue.

Storage? Cool, dry, dark. Foil-laminate sachets are stable at room temperature; no refrigeration required. Avoid bathroom storage (humidity).

Where can I see the COA? Per-batch certificate of analysis available on request via our contact page.

Where this sits in the catalog — the architecture

True Health Protocol's longevity catalog is structured in concentric layers. NR drink mix (this product) sits in the Layer 1 NAD+ Precursor Supply position, alongside our capsule NR and NMN entries. Layer 1 = precursor supply (what feeds NAD+). Layer 2 = sirtuin activators (Resveratrol, Pterostilbene). Layer 3 = methylation + CD38 reduction (TMG, Apigenin, Quercetin, Fisetin). Layer 4 = mitochondrial cofactors (CoQ10, PQQ, Urolithin A, CaAKG). Layer 5 = autophagy + proteostasis (Spermidine). Layer 6 = AMPK pathway (Berberine, ALA). Layer 7 = antioxidant + glutathione (NAC, Glutathione, Glycine, ALA, Liposomal Vit C). Layer 8 = foundational daily (Mg, D3+K2, Omega-3, Curcumin). The right user picks one entry per layer based on goals, format preference, and what's already in the routine. This drink covers Layer 1 in drink format.

Related collections

• NAD+ Family — all NAD+ precursors, activators, and convenience formulas
• Foundational Health — the 7 daily nutrients underneath every longevity stack
• Longevity Essentials — the core stack
• Mitochondrial Renewal — CoQ10, PQQ, Urolithin A, Ca-AKG
• Senolytics — Fisetin, Quercetin, Apigenin
• Cardiovascular Longevity — Resveratrol, Omega-3, CoQ10
• Metabolic — AMPK + glucose-handling layer

Read more on this topic

• What is NAD+? A beginner's guide to the coenzyme behind longevity
• NMN vs NR — which NAD+ precursor actually works better
• NMN vs NAD+ — which should you take in 2026
• Best time to take NMN — morning, empty stomach, or with food
• Longevity Stacking Protocol 2026
• Mitochondrial Renewal — how to clear damaged mitochondria and build new ones
• Foundational Health — the 7 daily nutrients underneath every longevity stack
• Best energy supplements that aren't caffeine
• Longevity supplements after 40 — what changes and what to add
• NMN side effects — what the research actually shows

Selected references

Context, not endorsement. Citations describe the underlying biology and human-clinical-trial evidence base for NAD+ pathway support; statements about this specific product have not been evaluated by the FDA.

• Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117(4):495–502.
• Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.
• Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9(1):9772.
• Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
• Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. AJCN. 2018;108(2):343–353.
• Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome. Cell Reports. 2019;28(7):1717–1728.
• Remie CME, Roumans KHM, Moonen MPB, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. AJCN. 2020;112(2):413–426.
• Stocks B, Ashcroft SP, Joanisse S, et al. Nicotinamide riboside supplementation does not alter whole-body or skeletal muscle metabolic responses to a single bout of endurance exercise in healthy older men. J Physiol. 2021;599(5):1513–1531.
• Brakedal B, Dolle C, Riemer F, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. 2022;34(3):396–407.
• Brakedal B, Toker L, Haugarvoll K, et al. A nationwide study of NR-SAFE: a randomized double-blind safety trial of high-dose nicotinamide riboside in Parkinson's disease. Nat Commun. 2023;14(1):5751.
• Pirinen E, Auranen M, Khan NA, et al. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism. 2020;31(6):1078–1090.
• Dellinger RW, Santos SR, Morris M, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably. NPJ Aging. 2017;3:17.
• Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLOS ONE. 2017;12(12):e0186459.
• Ratajczak J, Joffraud M, Trammell SAJ, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:13103.
• Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE. 2012;7(7):e42357.
• Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127–1139.
• Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism. 2011;14(4):528–536.
• Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
• Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47–57.
• Luongo TS, Eller JM, Lu MJ, et al. SLC25A51 is a mammalian mitochondrial NAD+ transporter. Nature. 2020;588(7836):174–179.
• Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008;134(2):317–328.
• Howitz KT, Bass GT, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–196.
• Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421–433.
• Escande C, Nin V, Price NL, et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013;62(4):1084–1093.
• Madeo F, Eisenberg T, Pietrocola F, Kroemer G. Spermidine in health and disease. Science. 2018;359(6374):eaan2788.
• Sekhar RV. GlyNAC supplementation improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, aging hallmarks, metabolic defects, muscle strength, cognitive decline, and body composition. Clin Transl Med. 2021;11(8):e372.
• Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717.
• Bitterman KJ, Anderson RM, Cohen HY, et al. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. JBC. 2002;277(47):45099–45107.
• Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. Am J Clin Nutr. 2003;133(12):4135–4138.
• López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217.
• López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243–278.

Browse the full NAD+ Family · Longevity Essentials · Foundational Health

This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. Consult your physician before starting any supplement, especially if you take prescription medication, are pregnant or breastfeeding, or have a medical condition.